Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year Low - Should You Sell?

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock price hit a new 52-week low on Thursday . The stock traded as low as $22.26 and last traded at $22.26, with a volume of 35086 shares traded. The stock had previously closed at $22.57.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GMAB. Truist Financial cut their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, September 9th. Royal Bank of Canada upgraded Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. Redburn Atlantic started coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a "buy" rating for the company. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Wednesday, October 16th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $45.20.

Genmab A/S Stock Performance

The stock has a market capitalization of $14.77 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 0.68 and a beta of 0.98. The stock's 50 day moving average is $25.07 and its two-hundred day moving average is $26.69.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The firm had revenue of $779.50 million during the quarter, compared to analyst estimates of $734.60 million. Equities research analysts expect that Genmab A/S will post 1.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of GMAB. Russell Investments Group Ltd. boosted its holdings in shares of Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock worth $28,000 after purchasing an additional 544 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Genmab A/S during the first quarter worth $43,000. Blue Trust Inc. increased its stake in shares of Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock worth $108,000 after acquiring an additional 3,880 shares during the last quarter. Headlands Technologies LLC raised its holdings in shares of Genmab A/S by 1,702.8% during the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company's stock worth $129,000 after acquiring an additional 4,853 shares during the period. Finally, Benjamin F. Edwards & Company Inc. raised its holdings in shares of Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock worth $182,000 after acquiring an additional 478 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.